Pharma Focus Asia
KP - Sustainable Packaging Solutions

AstraZeneca pharmaceutical invests $200 million for Frederick, Maryland biologics manufacturing center expansion

Introduction

AstraZeneca announced plans to expand its biologics manufacturing center in Frederick, Maryland with an investment of more than $200 million. The expansion of this project is expected to complete in mid-2017.

Features

AstraZeneca’s Frederick biologics manufacturing center is an FDA licensed, large-scale cell culture production facility. The site currently produces a pediatric medication, as well as other investigational biologic products.

This project will increase production capacity at the facility to support AstraZeneca’s maturing pipeline, and will help position the company to keep pace with a growing demand for the development and use of biologics, which currently represent nearly 50% of AstraZeneca’s overall pipeline.

The expansion project will add approximately 40,000 additional square feet of manufacturing, laboratory and administrative space. The expansion is also expected to bring a total of 300 new jobs to the site.

Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?